DATASHEET
Host:
Rabbit
Target Protein:
C5a anaphylatoxin
Immunogen Range:
701-755/1680
Clonality:
Polyclonal
Isotype:
IgG
Entrez Gene:
15139
Swiss Prot:
P06684
Source:
KLH conjugated synthetic peptide derived from mouse C5a (725-770aa)
Purification:
Purified by Protein A.
Storage Buffer:
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage:
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Background:
Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.
PRODUCT SPECIFIC PUBLICATIONS
- Miyabe, Yoshishige, et al. "Complement C5a receptor is the key initiator of neutrophil adhesion igniting immune complex–induced arthritis." Science Immunology 2.7 (2017): eaaj2195.Read more>>
VALIDATION IMAGES
Mouse thymus lysate probed with C5a anaphylatoxin Polyclonal Antibody, Unconjugated (bs-0324R) at 1:300 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:10000 for 60 min at 37˚C.
Mouse thymus lysates probed with C5a anaphylatoxin Polyclonal Antibody, Unconjugated (bs-0324R) at 1:300 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.
Lane 1: Human A549 cell lysates; Lane 2: Human Hela cell lysates probed with C5a Polyclonal Antibody, Unconjugated (bs-0324R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at room temperature for 60 min.